Abstract
Aims/hypothesis
This study aimed to assess the causal relationship between visceral obesity and type 2 diabetes and subsequently to screen visceral adipose tissue (VAT)-specific targets for type 2 diabetes.
Methods
We examined the causal relationship between VAT and type 2 diabetes using bidirectional Mendelian randomisation (MR) followed by multivariable MR. We conducted a transcriptome-wide association study (TWAS) leveraging prediction models and a large-scale type 2 diabetes genome-wide association study (74,124 cases and 824,006 controls) to identify candidate genes in VAT and used summary-data-based MR (SMR) and co-localisation analysis to map causal genes. We performed enrichment and single-cell RNA-seq analyses to determine the cell-specific localisation of the TWAS-identified genes. We also conducted knockdown experiments in 3T3-L1 pre-adipocytes.
Results
MR analyses showed a causal relationship between genetically increased VAT mass and type 2 diabetes (inverse-variance weighted OR 2.48 [95% CI 2.21, 2.79]). Ten VAT-specific candidate genes were associated with type 2 diabetes after Bonferroni correction, including five causal genes supported by SMR and co-localisation: PABPC4 (1p34.3); CCNE2 (8q22.1); HAUS6 (9p22.1); CWF19L1 (10q24.31); and CCDC92 (12q24.31). Combined with enrichment analyses, clarifying cell-type specificity with single-cell RNA-seq data indicated that most TWAS-identified candidate genes appear more likely to be associated with adipocytes in VAT. Knockdown experiments suggested that Pabpc4 likely contributes to regulating differentiation and energy metabolism in 3T3-L1 adipocytes.
Conclusions/interpretation
Our findings provide new insights into the genetic basis and biological processes of the association between VAT accumulation and type 2 diabetes and warrant investigation through further functional studies to validate these VAT-specific candidate genes.
Graphical Abstract
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Central adiposity, also known as abdominal adiposity, represents an accumulation of excessive visceral fat. It is usually captured by anthropometric measures such as waist circumference or WHR and has been related to type 2 diabetes independent of BMI. Imaging-based studies have shown that individuals with type 2 diabetes tend to have more visceral fat than BMI-matched individuals without type 2 diabetes [1, 2]. However, these studies were largely limited by small sample sizes and were prone to be influenced by potential environmental and behavioural confounding factors and reverse causation, restricting their ability for causal inference.
It is well known that visceral adipose tissue (VAT) is more harmful than adipose tissue from other locations [3], such as subcutaneous adipose tissue (SAT) and adipose tissue from the extremities. Several studies have focused on the underlying molecular mechanisms and links between visceral fat accumulation and type 2 diabetes, including dysfunctional VAT characterised by adipocyte hypertrophy, the dysregulation of adipocytokines, changes in extracellular matrix (ECM) composition and function, and increased infiltration of inflammatory immune cells [4, 5], each of which may present potential novel therapeutic avenues. Therefore, VAT is a key target organ in which novel molecules and pathways linked to type 2 diabetes pathogenesis could be identified. However, the precise mechanisms require further elucidation.
In the past 10 years, genome-wide association studies (GWAS) have become a powerful tool, not only for revealing the genetic basis and providing the starting point for further studies of potential mechanisms but also for the development of Mendelian randomisation (MR) to make causal inferences in complex diseases. Nevertheless, although more than 200 loci related to type 2 diabetes risk have been identified from the largest GWAS to date [6], it is likely that many loci contributing to type 2 diabetes pathogenesis were missed due to the stringent statistical threshold that is typically used. In addition, the biological interpretation of genetic association results remains a major challenge because most GWAS-identified variants are located in non-coding or intergenic regions, indicating the presence of regulatory mechanisms of gene expression [7, 8]. What is more, these genetic associations carry no information on tissue specificity. Recently, a transcriptome-wide association study (TWAS) was reported to be useful for systematically detecting disease susceptibility genes across various tissues by imputing predicted gene expression into GWAS datasets [9]. TWAS-identified genes are essential to explore disease aetiology, facilitate interpretation of the biological process of GWAS findings and prioritise follow-up functional studies.
In this study, we performed two-sample MR analyses to evaluate the causal effects of genetically increased VAT mass on type 2 diabetes risk. We then utilised the pretrained genetic prediction models established by the three most advanced strategies. We reported results from a large type 2 diabetes TWAS conducted among nearly 900,000 participants of European ancestry to comprehensively identify VAT-specific candidate genes that contribute to type 2 diabetes risk. To validate these in silico findings, we further performed in vitro functional experiments for one gene, PABPC4, encoding poly(A) binding protein cytoplasmic 4 (PABPC4).
Methods
Study design
The study flow chart is depicted in Fig. 1. Overall, we utilised a series of MR (inverse-variance weighted [IVW], weighted median, MR-Egger regression, MR-pleiotropy residual sum and outlier [MR-PRESSO], MR-robust adjusted profile score [MR-RAPS], causal analysis using summary effect estimates [CAUSE] and generalised summary-data-based MR [GSMR]) and TWAS, combined with single-cell RNA-seq and enrichment analyses to identify and localise casual genes. Finally, we conducted in vitro experiments to validate the TWAS findings. See ESM Methods for details.
Univariable and multivariable MR analysis
Selection of exposures
The UK Biobank enrolled more than 500,000 participants aged 40–69 years old from the UK between 2006 and 2010. The summary data for predicted VAT mass were acquired from a recent large-scale GWAS (GWAS Catalog ID: GCST008744). We then extracted four variables from the GWAS summary data, including BMI, waist circumference and WHR, from the Genetic Investigation of ANthropometric Traits consortium (GIANT; https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files, accessed 19 February 2022) and smoking status from the UK Biobank (downloaded from MR-Base database, https://www.mrbase.org/, accessed on 19 February 2022) to serve as confounding factors to be adjusted in multivariable MR analysis. See ESM Methods for details.
Selection of outcomes
We collected the summary data for type 2 diabetes from the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM; http://diagram-consortium.org/downloads.html, accessed 25 February 2022) consortium and 70KforT2D GWAS project (https://kp4cd.org/node/151, accessed 25 February 2022). The glucose-related traits, such as HbA1c, fasting glucose (FG), 2h glucose (2hGlu) and fasting insulin, were obtained from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC; https://magicinvestigators.org/, accessed 27 February 2022). See ESM Methods for details.
Transcriptome-wide association analysis
We used the recently released data for VAT and SAT from the Genotype-Tissue Expression (GTEx; https://gtexportal.org/home/, accessed 5 March 2022) project (V8), and utilised the pretrained prediction models from Zenodo (https://doi.org/10.5281/zenodo.3842289, accessed 7 March 2022) for further TWAS analysis. See ESM Methods for details.
In vitro experimental assays for functional validation
We conducted knockdown experiments on mouse 3T3-L1 adipocytes for the genes with the highest priority. Briefly, we used western blot (peroxisome proliferator-activated receptor γ [PPARG], protein kinase AMP-activated catalytic subunit α 1 and 2 [PRKAA1/2], IRS1 and GLUT1), quantitative real-time PCR (qPCR) (Adipoq, Plin1, Cidec, Lipe, Lep and Pnpla2), ELISA (IL-6, TNF-α and monocyte chemoattractant protein-1 [MCP-1] in medium), glucose consumption assays and Oil Red O staining to assess the effects of Pabpc4 knockdown on the energy and lipid metabolism, secretory functions, glucose utilisation and insulin signalling, respectively, in adipocytes. See ESM Methods for details.
Statistical analysis
LD score regression analysis
We applied linkage disequilibrium (LD) score regression between VAT and type 2 diabetes with GWAS summary statistics using LDSC software version 1.0.1 (https://github.com/bulik/ldsc/, accessed on 1 February 2022). See ESM Methods for details.
Univariable and multivariable MR analysis
We performed univariable and bidirectional two-sample MR with seven MR methods, and we took the IVW results as the primary associations while also considering the consistency of the results across other MR methods. See ESM Methods for details.
Transcriptome-wide association analysis
We used three different approaches to perform a summary-based TWAS using MetaXcan TWAS pipeline (https://github.com/hakyimlab/MetaXcan, accessed 7 March 2022). See ESM Methods for details.
Summary-data-based MR and co-localisation
We performed summary-data-based MR (SMR), heterogeneity in dependent instrument (HEIDI) test, and co-localisation analysis to further screen ‘causal genes’ [p (SMR) passing Bonferroni correction, HEIDI p>0.05 and posterior probability of a hypothesis (PPH)4 >0.70]. See ESM Methods for details.
Bulk RNA-seq and enrichment analysis
We analysed publicly available bulk RNA-seq data from VAT samples of individuals with type 2 diabetes to validate the expression of TWAS-identified genes. We performed functional enrichment analysis to annotate these genes in a biological context using Data-driven Expression Prioritized Integration for Complex Traits tool [10] (DEPICT, https://github.com/perslab/depict, accessed 10 March 2022) and FUMA tool [11] version 1.4.1 (https://github.com/Kyoko-wtnb/FUMA-webapp/). See ESM Methods for details.
Single-cell analysis for the stromal vascular fraction and adipocyte differential gene analysis in VAT
We examined the cell-type-specific expression of the ten candidate genes by using human VAT single-cell RNA-seq data (GEO database accession no. GSE136230). See ESM Methods for details.
Analysis software
MR analyses were performed in R (version 4.1.0) [12] with the R packages ‘TwoSampleMR’ (version 0.5.5, https://mrcieu.github.io/TwoSampleMR/) [13], ‘MRPRESSO’ (version 1.0, https://github.com/rondolab/MR-PRESSO) [14], ‘CAUSE’ (version 1.2.0, https://github.com/jean997/cause) [15], ‘gsmr’ (version 1.0.9, https://yanglab.westlake.edu.cn/software/gsmr/) [16] and ‘MVMR’ (version 0.3, https://github.com/WSpiller/MVMR) [17]. TWAS analyses were performed in Python (version 3.9.1) with a Python script in the MetaXcan pipeline. SMR and HEIDI test were performed by the SMR software tool (version 1.3.1; https://yanglab.westlake.edu.cn/software/smr/#Download).
Results
Univariable and multivariable MR analyses
Participant characteristics and genetic correlations are shown in ESM Results and ESM Tables 1, 2. In total, 221 SNPs were selected as instrumental variables (IVs) for predicted VAT mass based on the IV assumptions in MR analysis (ESM Tables 1, 3 and ESM Fig. 1). Univariable MR showed a causal relationship between the predicted VAT mass and type 2 diabetes risk and HbA1c levels across six MR approaches (VAT and type 2 diabetes with an IVW OR 2.48 [95% CI 2.21, 2.79], and see other results in ESM Results, ESM Table 4 and ESM Figs 2–8). To reduce the possibility of reverse causation, a bidirectional MR was conducted using the GSMR in combination with other MR methods (Table 1, Fig. 2a,b and ESM Table 5). The forward GSMR suggested an adverse effect of the predicted increased VAT on the type 2 diabetes risk (OR 2.70 [95% CI 2.46, 2.96], p=3.12×10−99 for discovery analysis; OR 1.65 [95% CI 1.46, 1.87], p=1.05×10−15 for replication analysis). The reverse GSMR showed a significant association between genetically determined type 2 diabetes and a higher VAT mass; however, the ORs were very close to the null value (0.99 [95% CI 0.98, 1.00]). Notably, the causal relationships from other reverse MR (using two-sample MR analysis) were no longer significant (ESM Table 5). There was little evidence to support an association between genetically increased glucose-related traits and VAT mass (ESM Table 4). Sensitivity analysis showed evidence of heterogeneity but without horizontal pleiotropy between VAT and type 2 diabetes (see ESM Results ‘Sensitivity analysis’ and ESM Table 6).
Taking into account the results of the univariable MR analysis, multivariable MR was performed to further determine the independent effects of VAT adjusted for potential confounders. We found that the strong positive associations between VAT and type 2 diabetes persisted using the two multivariable MR methods (except for the association adjusted for BMI, which was attenuated). The multivariable-adjusted ORs (95% CIs) were 2.60 (1.91, 3.54) adjusted for BMI, 2.08 (1.59, 2.72) adjusted for waist circumference, 2.49 (2.09, 2.97) adjusted for WHR and 2.70 (2.32, 3.14) adjusted for smoking status (Fig. 2c). Although the relationship between the predicted VAT and type 2 diabetes was attenuated after adjustment for waist circumference in replication analysis, it still showed the same effect direction and overlapped CIs as the univariable results (Fig. 2c).
Transcriptome-wide association analysis
Using joint-tissue imputation (JTI), PrediXcan and modified unified test for molecular signatures (UTMOST), three separate prediction models were built and detailed information on the prediction performance for each gene is shown in ESM Tables 7–12. The JTI framework, PrediXcan and UTMOST prioritised 132 genes (Bonferroni-corrected p<4.04×10−6), 88 genes (p<6.14×10−6) and 116 genes (p<5.34×10−6), respectively. The Manhattan plots using the three TWAS methods are shown in ESM Fig. 9. As a next step, in our gene-prioritisation strategy, the SMR prioritised 42 candidate genes. Finally, 25 genes were identified by all methods.
To compare the expression of genes contributing to type 2 diabetes risk with VAT, the same analyses were repeated to identify candidate genes expressed in SAT using GTEx data. Finally, 32 genes were identified by all methods. There were ten VAT-related genes (five novel type 2 diabetes-associated genes) showing no significant gene-level TWAS associations in SAT-related analysis and thus they represent independent hits (Table 2). At the 1p34.3 locus, genetically elevated expression of PABPC4 was associated with decreased type 2 diabetes risk. Besides, genetically elevated expression of CCNE2 on 8q22.1, HAUS6 on 9p22.1, CWF19L1 on 10q24.31, CCDC92 on 12q24.31 and DNAH10OS on 12q24.31 showed protective effects on type 2 diabetes risk. All these associations were further filtered by co-localisation between the gene expression and type 2 diabetes associations (PPH4 >0.70) and the SMR HEIDI test (p>0.05). Four other genes identified in the TWAS failed to be confirmed by co-localisation analysis or the SMR HEIDI test. The detailed TWAS and SMR results are shown in ESM Tables 7–14.
Bulk RNA-seq and enrichment analysis
According to the analysis of bulk RNA-seq data, three significantly differentially expressed TWAS-identified genes were observed when comparing individuals with type 2 diabetes and non-diabetic individuals with morbid obesity: PABPC4 (p=0.004); HAUS6 (p=0.011); and DNLZ (p=0.013). Moreover, HLA-DRB1 (p=0.086) and CWF19L1 (p=0.100) reached the margin of significance (Fig. 3a).
Adipose tissue and adipocytes showed the strongest enrichment using the DEPICT tool (Fig. 3b–d and ESM Table 15). A pathway analysis for JTI-identified genes using FUMA detected several significantly associated Gene Ontology gene sets. The top five sets were MHC protein complex assembly (p=6.26×10−7), activating transcription factor 6 (ATF6)-mediated unfolded protein response (p=3.72×10−6), negative regulation of insulin secretion (p=6.64×10−6), negative regulation of signalling (p=7.26×10−6) and cell cycle process (p=7.32×10−6). The results for all enriched pathways with a false discovery rate of <0.05 are presented in ESM Table 16.
Single-cell analysis for the stromal vascular fraction and adipocytes differential gene analysis in VAT
Enrichment analysis suggested that adipocytes might be associated with type 2 diabetes risk. It is important to note that adipose tissue is a complex and highly active organ that is composed of two main cell populations (adipocytes and the stromal vascular fraction [SVF; immune cells, pre-adipocytes, endothelial cells, etc.]). Therefore, single-cell RNA-seq data of SVF in VAT were re-analysed. After filtering, 12,897 SVF cells (4888 cells from individuals with type 2 diabetes and 8009 cells from individuals without diabetes) were obtained. Annotation of the clusters using recommended marker genes resulted in the following ten cell types: tissue stem cells; smooth muscle cells; fibroblasts; macrophages; natural killer (NK) cells; T cells; endothelial cells; monocytes; B cells; and chondrocytes (Fig. 3e), showing different expression patterns (Fig. 3f). The cell distribution in individuals with type 2 diabetes was clearly distinct from that in individuals without diabetes (Fig. 3e). Notably, most TWAS-identified genes did not show differential expression between the two groups, except for a higher expression of NEAT1 in fibroblasts, macrophages and endothelial cells in individuals with type 2 diabetes and a higher expression of HLA-DRB1 and ZNF34 in fibroblasts and T cells in individuals without diabetes (Fig. 3g). In addition, PABPC4 and ZNF34 differed in their expression patterns in adipocytes (Fig. 3g). In general, among these findings, PABPC4 exhibited a good agreement at different omics levels, including genetics, bulk RNA-seq (Fig. 3a; two additional GEO datasets are shown in ESM Fig. 10) and single-cell RNA-seq analysis.
In vitro experimental assays for functional validation
Based on the above analysis of the results, the expression of PABPC4 in adipocytes was speculated to be related to type 2 diabetes risk. This finding was strengthened further by a series of knockdown experiments in mouse 3T3-L1 adipocytes. The experimental materials, reagents and primer sequences are shown in ESM Tables 17–18. Pabpc4 knockdown was confirmed by conducting both western blot and qPCR analysis, both showing a significant decrease compared with the control group transfected with empty vector. Knockdown of Pabpc4 inhibited the expression of PPARG (tested before the induction of the differentiation), PRKAA1/2 and IRS1 under basal conditions, representing the regulation of cell differentiation, energy metabolism and insulin signalling, respectively. Only GLUT1 was upregulated especially in the insulin-stimulated group (Fig. 4a). Further, similar changes in protein expression were noted in response to Pabpc4 knockdown under insulin conditions (Fig. 4a,b). Glucose consumption experiments showed that knockdown of Pabpc4 inhibited the glucose utilisation of 3T3-L1 adipocytes (Fig. 4c). Given the effect of Pabpc4 knockdown on glucose uptake, insulin signalling experiments with p-Akt assessment were conducted, showing a significant downregulation in Akt signalling (ESM Fig. 11). Oil Red O staining indicated that Pabpc4 might be associated with the lipid storage capacity of adipocytes (Fig. 4d). Measurement of lipid metabolism-related genes showed that Adipoq and Lipe were downregulated while Cidec was upregulated (Fig. 4e). The supernatant fractions of adipocyte cell cultures were assayed for IL-6, TNF-α and MCP-1, showing a consistent downregulation under insulin conditions (Fig. 4f).
Discussion
In this study, we provided evidence that VAT mass was genetically correlated with type 2 diabetes and HbA1c using whole-genome LDSC. Two-sample and bidirectional MR analyses suggested that genetically determined VAT mass was causally related to an increased risk of type 2 diabetes and a higher level of HbA1c but not vice versa. Furthermore, utilising the reference data for VAT and SAT from the GTEx project, TWAS analyses identified ten VAT-specific genes related to type 2 diabetes risk. Of these, five putative target genes, including PABPC4 on 1p34.3, CCNE2 on 8q22.1, HAUS6 on 9p22.1, CWF19L1 on 10q24.31 and CCDC92 on 12q24.31, were labelled ‘causal genes’ according to the SMR and co-localisation analyses. Knockdown experiments in 3T3-L1 adipocytes indicated that Pabpc4 may have a role in regulating the differentiation and energy metabolism.
The genetic relationship between obesity-related traits (e.g. BMI, waist circumference and WHR) and type 2 diabetes has already been established [18, 19] but this relationship has not been established for VAT. A population-based twin study found a significantly higher genetic correlation between insulin resistance and central fat (r = 0.41) than that for total fat (0.24) [20]. These findings illustrated that central fat is not only a predictor of insulin resistance but also shares genetic influence with insulin resistance, which is a major factor in obesity-linked type 2 diabetes. We found significant genetic correlations of VAT with type 2 diabetes and HbA1c, but not FG, 2hGlu or fasting insulin, suggesting that VAT accumulation might be associated with persistent dysglycaemia. Furthermore, most observational studies have specifically investigated the association between imaging-measured VAT and type 2 diabetes risk with a limited sample size. A recent study, using dual-energy x-ray absorptiometry (DXA) to accurately measure VAT in more than 4000 participants, reported a strong association between VAT mass and type 2 diabetes risk (OR [95% CI] 8.55 [4.48, 16.3] for female participants and 2.01 [1.56, 2.58] for male participants). VAT was a stronger risk factor in the female participants while the higher overall prevalence of type 2 diabetes in the male participants could be ascribed to their larger average depot of VAT [21]. These associations were verified by MR analyses, suggesting a causal role of the predicted VAT on type 2 diabetes [21].
Nevertheless, the sample size of that study was relatively small (9517 type 2 diabetes cases), and the MR estimations were not adjusted for potential confounders such as BMI. In comparison, our MR analyses leveraged a larger sample size (26,676 type 2 diabetes cases in discovery analysis and 12,931 cases in replication analysis) to make causal inference and obtained an independent effect of VAT that was independent from BMI, waist circumference, WHR and smoking status. These analyses indicated that targeting body fat distribution, especially VAT, might be a promising strategy for type 2 diabetes. However, the specific mechanisms involved in the pathogenesis of type 2 diabetes associated with VAT remain to be elucidated. Thus, the candidate genes identified by TWAS could provide a new direction for unravelling the shared aetiologies between VAT and type 2 diabetes since genetic regulatory variation is the major determinant of target gene expression and subsequently alters the levels of proteins [22, 23].
Usually, there are two possibilities for the relationship between gene expression alterations and disease status: one is that the altered gene expression leads to disease conditions (potential targets); and the other is that the disease itself results in aberrant gene expression (biomarkers). Using TWAS analyses, several candidate genes identified in both VAT and SAT have been studied more extensively. For example, IRS1 is a substrate of insulin receptor tyrosine kinase, which plays an important role in insulin-stimulated signal transduction pathway. Kilpeläinen et al identified a locus near IRS1 that was associated with increased body fat but it was a robustly protective locus for cardiometabolic risk including type 2 diabetes and coronary artery disease [24]. Juxtaposed with another zinc finger protein 1 (JAZF1) is a transcriptional coregulator associated with pathophysiological processes in type 2 diabetes, as confirmed by animal studies. Overexpression of JAZF1 inhibits glucose production by the liver [25]. It also acts as an important regulator of endoplasmic reticulum stress, preventing p53-mediated metabolic stress in beta cells [26]. WFS1 mutation leads to the Wolfram syndrome, of which the most common clinical phenotypes are early onset diabetes and neurological symptoms. Wfs1-knockout rats show a strikingly different diabetic phenotype compared with previous animal models [27].
However, the aforementioned genes cannot reflect the unique contribution made by VAT to type 2 diabetes. We identified ten VAT-specific genes that were related to type 2 diabetes. These included eight protein-coding genes, three of which were verified in a bulk RNA-seq dataset. For several of our identified genes, there is already evidence from published studies supporting their potential role in the pathogenesis of type 2 diabetes. For instance, PABPC4 is localised primarily to the cytoplasm and is necessary for regulating the stability of labile mRNA. Furthermore, it has been identified as a putative functional gene for type 2 diabetes from the SMR analysis in the Consortium for the Architecture of Gene Expression (CAGE, N=2765 in peripheral blood) [28]. It was also reported that PABPC4 is necessary for the regulation of fat and glucose levels, especially when high-fat diets are consumed. Thus, it may form part of the important link between obesity and type 2 diabetes [29]. Consistently, our in vitro functional assays verified that the knockdown of Pabpc4 decreases glucose utilisation in 3T3-L1 adipocytes, and this process is less likely to be mediated by glucose transporters (GLUT1 was upregulated). Interestingly, it has been reported that glucose entrance through GLUT1 with activation of the hexosamine pathway may decrease the insulin-mediated glucose transport through GLUT4, leading to insulin resistance [30]. In contrast, AMP-activated protein kinase (AMPK), a key cellular sensor of energy balance that regulates energy metabolism [31], may be a molecular signalling pathway downstream of PABPC4. We observed that the expression levels of PRKAA1/2 and p-Akt were downregulated in the shRNA groups. Therefore, we speculate that the effect of Pabpc4 knockdown on glucose consumption may be achieved through the AMPK and Akt signalling pathway.
Moreover, the decreased Pparg expression suggested that Pabpc4 may be involved in pre-adipocyte differentiation, which has been shown to be related to adipocyte insulin resistance [32]. Examination of lipid metabolism-related genes provided some clues to explain how Pabpc4 knockdown affects adipocyte lipid storage capacity. For example, Adipoq gene promotes glucose uptake and fatty acid oxidation in adipocytes and regulates adipocyte energy metabolism and insulin sensitivity [33]. Lipe, encoding kinase-sensitive lipase (HSL), is a key enzyme in triacylglycerol catabolism in adipocytes [34]. Cidec has been proven to be involved in the formation and maintenance of lipid droplets in adipocytes. Knockdown of Cidec in well-differentiated adipocytes enhances lipolysis, increases the number of mitochondria and increases the expression of genes associated with brown adipocyte identity [35].
Other TWAS-identified causal genes, such as CWF19L1, are likely to be involved in cell cycle regulation and are well conserved in several species. However, there have been no experimental studies that link the expression of CWF19L1 with type 2 diabetes. Previous research has shown that common variants of the ERLIN1–CHUK-CWF19L1 gene cluster act in fatty liver and metabolic diseases [36]. CCDC92 encodes a coiled-coil domain protein that can interact with proteins at the centriole–ciliary interface. In a bivariate GWAS, a novel signal at rs825476 near CCDC92, which is also an expression quantitative trait locus (eQTL) for this gene, was identified as a shared locus between type 2 diabetes and CHD [37]. The effects of two other causal genes, CCNE2 and HAUS6, on type 2 diabetes have not been validated in functional studies and will need to be investigated in future research.
Strength and limitations
To the best of our knowledge, this study is the first to systematically identify VAT-specific candidate genes that are associated with type 2 diabetes risk using TWAS analyses. TWAS-identified genes are more appropriately interpreted as prioritised genes at relative loci, meaning that these genes do not imply causality. Thus, we used different approaches, such as TWAS, SMR and co-localisation, to confirm and complement each other, making the results more reliable. Moreover, we re-analysed and combined the single-cell RNA-seq data to determine the cell-type specificity for these candidate genes.
Notably, it should be emphasised that there are also three major limitations in our study. First, the relatively small sample size for GTEx reference data of VAT limits the precision and power to detect associations less of moderate strength. VAT is a heterogeneous tissue containing many cell types (organ-specific and migratory) with relative proportions that can vary according to the harvesting location and environmental factors. Second, TWAS only focuses on genes with significant cis-heritability (cis-eQTLs, within a certain distance from gene body). However, the expression of some genes can be regulated by trans-regulatory elements in the human genome; thus, the importance of trans-eQTLs in transcriptional regulation should not be overlooked. Third, the reference data we used in TWAS were mainly of European ancestry due to the lack of large-scale eQTL data from other ancestry groups, diseases, medical conditions, sex, etc., limiting the generalisability of the findings to other ethnic groups.
Conclusions
In summary, our findings provide substantial new information to improve our understanding of the genetics and aetiology of type 2 diabetes and lay a foundation for further functional studies of these identified target genes to thoroughly explore the in-depth mechanisms.
Abbreviations
- 2hGlu:
-
2 h glucose
- AMPK:
-
AMP-activated protein kinase
- CAUSE:
-
Causal Analysis Using Summary Effect Estimates
- DIAGRAM:
-
DIAbetes Genetics Replication And Meta-analysis
- ECM:
-
Extracellular matrix
- eQTL:
-
Expression quantitative trait locus
- FG:
-
Fasting glucose
- GIANT:
-
Genetic Investigation of ANthropometric Traits consortium
- GSMR:
-
Generalised summary-data-based MR
- GTEx:
-
Genotype-Tissue Expression
- GWAS:
-
Genome-wide association study
- HEIDI:
-
Heterogeneity in dependent instrument
- IV:
-
Instrumental variable
- IVW:
-
Inverse-variance weighted
- JTI:
-
Joint-tissue imputation
- LD:
-
Linkage disequilibrium
- MAGIC:
-
Meta-Analyses of Glucose and Insulin-related traits Consortium
- MCP-1:
-
Monocyte chemoattractant protein-1
- MR:
-
Mendelian randomisation
- MR-PRESSO:
-
MR-pleiotropy residual sum and outlier
- MR-RAPS:
-
MR-robust adjusted profile score
- PABPC4:
-
Poly(A) binding protein cytoplasmic 4
- PPH:
-
Posterior probability of a hypothesis
- qPCR:
-
Quantitative real-time PCR
- SAT:
-
Subcutaneous adipose tissue
- SMR:
-
Summary-data-based MR
- SVF:
-
Stromal vascular fraction
- TWAS:
-
Transcriptome-wide association study
- UTMOST:
-
Unified test for molecular signatures
- VAT:
-
Visceral adipose tissue
References
Gallagher D, Kelley DE, Yim JE et al (2009) Adipose tissue distribution is different in type 2 diabetes. Am J Clin Nutr 89(3):807–814. https://doi.org/10.3945/ajcn.2008.26955
Jung SH, Ha KH, Kim DJ (2016) Visceral fat mass has stronger associations with diabetes and prediabetes than other anthropometric obesity indicators among Korean adults. Yonsei Med J 57(3):674–680. https://doi.org/10.3349/ymj.2016.57.3.674
Fox CS, Massaro JM, Hoffmann U et al (2007) Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116(1):39–48. https://doi.org/10.1161/circulationaha.106.675355
Guo Z, Hensrud DD, Johnson CM, Jensen MD (1999) Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes 48(8):1586–1592. https://doi.org/10.2337/diabetes.48.8.1586
Votruba SB, Jensen MD (2007) Regional fat deposition as a factor in FFA metabolism. Annu Rev Nutr 27:149–163. https://doi.org/10.1146/annurev.nutr.27.061406.093754
Mahajan A, Taliun D, Thurner M et al (2018) Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet 50(11):1505–1513. https://doi.org/10.1038/s41588-018-0241-6
Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ (2010) Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet 6(4):e1000888. https://doi.org/10.1371/journal.pgen.1000888
Hindorff LA, Sethupathy P, Junkins HA et al (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 106(23):9362–9367. https://doi.org/10.1073/pnas.0903103106
Zhou D, Jiang Y, Zhong X, Cox NJ, Liu C, Gamazon ER (2020) A unified framework for joint-tissue transcriptome-wide association and Mendelian randomization analysis. Nat Genet 52(11):1239–1246. https://doi.org/10.1038/s41588-020-0706-2
Pers TH, Karjalainen JM, Chan Y et al (2015) Biological interpretation of genome-wide association studies using predicted gene functions. Nat Commun 6(1):5890. https://doi.org/10.1038/ncomms6890
Watanabe K, Taskesen E, van Bochoven A, Posthuma D (2017) Functional mapping and annotation of genetic associations with FUMA. Nat Commun 8(1):1826. https://doi.org/10.1038/s41467-017-01261-5
R Core Team R (2013) R: A language and environment for statistical computing
Hemani G, Zheng J, Elsworth B et al (2018) The MR-Base platform supports systematic causal inference across the human phenome. eLife 7:e34408. https://doi.org/10.7554/eLife.34408
Verbanck M, Chen C-Y, Neale B, Do R (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 50(5):693–698. https://doi.org/10.1038/s41588-018-0099-7
Morrison J, Knoblauch N, Marcus JH, Stephens M, He X (2020) Mendelian randomization accounting for correlated and uncorrelated pleiotropic effects using genome-wide summary statistics. Nat Genet 52(7):740–747. https://doi.org/10.1038/s41588-020-0631-4
Zhu Z, Zheng Z, Zhang F et al (2018) Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat Commun 9(1):224. https://doi.org/10.1038/s41467-017-02317-2
Sanderson E, Davey Smith G, Windmeijer F, Bowden J (2018) An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol 48(3):713–727. https://doi.org/10.1093/ije/dyy262
Grarup N, Sandholt CH, Hansen T, Pedersen O (2014) Genetic susceptibility to type 2 diabetes and obesity: from genome-wide association studies to rare variants and beyond. Diabetologia 57(8):1528–1541. https://doi.org/10.1007/s00125-014-3270-4
Carlsson S, Ahlbom A, Lichtenstein P, Andersson T (2013) Shared genetic influence of BMI, physical activity and type 2 diabetes: a twin study. Diabetologia 56(5):1031–1035. https://doi.org/10.1007/s00125-013-2859-3
Samaras K, Nguyen TV, Jenkins AB et al (1999) Clustering of insulin resistance, total and central abdominal fat: same genes or same environment? Twin Res 2(3):218–225. https://doi.org/10.1375/136905299320565898
Karlsson T, Rask-Andersen M, Pan G et al (2019) Contribution of genetics to visceral adiposity and its relation to cardiovascular and metabolic disease. Nat Med 25(9):1390–1395. https://doi.org/10.1038/s41591-019-0563-7
Lappalainen T, Sammeth M, Friedländer MR et al (2013) Transcriptome and genome sequencing uncovers functional variation in humans. Nature 501(7468):506–511. https://doi.org/10.1038/nature12531
Guo Y, Chung W, Zhu Z et al (2019) Genome-wide assessment for resting heart rate and shared genetics with cardiometabolic traits and type 2 diabetes. J Am Coll Cardiol 74(17):2162–2174. https://doi.org/10.1016/j.jacc.2019.08.1055
Kilpeläinen TO, Zillikens MC, Stančákova A et al (2011) Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet 43(8):753–760. https://doi.org/10.1038/ng.866
Liao ZZ, Wang YD, Qi XY, Xiao XH (2019) JAZF1, a relevant metabolic regulator in type 2 diabetes. Diabetes Metab Res Rev 35(5):e3148. https://doi.org/10.1002/dmrr.3148
Kobiita A, Godbersen S, Araldi E et al (2020) The diabetes gene JAZF1 is essential for the homeostatic control of ribosome biogenesis and function in metabolic stress. Cell Rep 32(1):107846. https://doi.org/10.1016/j.celrep.2020.107846
Plaas M, Seppa K, Reimets R et al (2017) Wfs1- deficient rats develop primary symptoms of Wolfram syndrome: insulin-dependent diabetes, optic nerve atrophy and medullary degeneration. Sci Rep 7(1):10220. https://doi.org/10.1038/s41598-017-09392-x
Xue A, Wu Y, Zhu Z et al (2018) Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. Nat Commun 9(1):2941. https://doi.org/10.1038/s41467-018-04951-w
Nicola KG (2021) IMPC: Importance of PABPs in mammalian reproduction and physiology. University of Edinburgh (Lead Research Organisation), 2021. Available at: https://gtr.ukri.org/projects?ref=MR%2FP02419X%2F1#/, accessed 25 March 2022
Ebeling P, Koistinen HA, Koivisto VA (1998) Insulin-independent glucose transport regulates insulin sensitivity. FEBS Lett 436(3):301–303. https://doi.org/10.1016/s0014-5793(98)01149-1
Wu WK, Ivanova EA, Orekhov AN (2021) Gut microbiome: a possible common therapeutic target for treatment of atherosclerosis and cancer. Semin Cancer Biol 70:85–97. https://doi.org/10.1016/j.semcancer.2020.06.017
Engeli S, Negrel R, Sharma AM (2000) Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 35(6):1270–1277. https://doi.org/10.1161/01.hyp.35.6.1270
Yamauchi T, Kamon J, Minokoshi Y et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8(11):1288–1295. https://doi.org/10.1038/nm788
Lafontan M, Langin D (2009) Lipolysis and lipid mobilization in human adipose tissue. Prog Lipid Res 48(5):275–297. https://doi.org/10.1016/j.plipres.2009.05.001
Tanaka N, Takahashi S, Matsubara T et al (2015) Adipocyte-specific disruption of fat-specific protein 27 causes hepatosteatosis and insulin resistance in high-fat diet-fed mice. J Biol Chem 290(5):3092–3105. https://doi.org/10.1074/jbc.M114.605980
Feitosa MF, Wojczynski MK, North KE et al (2013) The ERLIN1-CHUK-CWF19L1 gene cluster influences liver fat deposition and hepatic inflammation in the NHLBI Family Heart Study. Atherosclerosis 228(1):175–180. https://doi.org/10.1016/j.atherosclerosis.2013.01.038
Zhao W, Rasheed A, Tikkanen E et al (2017) Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. Nat Genet 49(10):1450–1457. https://doi.org/10.1038/ng.3943
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Acknowledgements
Summary-level data for GWAS summary statistics with exposures and outcomes were contributed by the UK Biobank, GIANT, DIAGRAM, 70KforT2D and MAGIC consortium. Pretrained gene prediction models for TWAS were provided by D. Zhou from the Vanderbilt University Medical Center. We thank all investigators and authors for sharing these data.
Data availability
All data generated or analysed during this study are included in this main text.
Funding
This work was supported by grants from National key research and development program (2022YFC3602400, 2022YFC3602401), National Natural Science Foundation of China (82170437, 81974054), Central South University Innovation-Driven Research Program (2023CXQD007) and Natural Science Foundation of Hunan Province (2021JJ31039).
Authors’ relationships and activities
All authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
Contribution statement
HT, SZ, LZ and YLu conceived the study. JW and PD performed the cell experiments. YLi and YC collected and organised the experimental data. JW, PD, YLi and YC drafted the method and results sections, and assisted with the introduction and discussion sections. HT performed the statistical analyses and wrote the manuscript. BY, SZ, LZ and YLu interpreted the data and reviewed the manuscript. YLu revised the manuscript critically. All authors approved the final version. YLu is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Tang, H., Wang, J., Deng, P. et al. Transcriptome-wide association study-derived genes as potential visceral adipose tissue-specific targets for type 2 diabetes. Diabetologia 66, 2087–2100 (2023). https://doi.org/10.1007/s00125-023-05978-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00125-023-05978-5